AAA today announced that following a positive opinion issued by the European Medicines Agency in October 2016, the European Commission has approved SomaKit TOC™ 40 μg, a kit for radiopharmaceutical preparation of gallium (Ga 68) edotreotide solution for injection, for Positron Emission Tomography (PET) imaging of somatostatin receptor overexpression in adult patients with confirmed or suspected well-differentiated gastroenteropancreatic neuroendocrine tumors (GEPNETs) for localizing primary tumors and their metastases. The drug has 10-year orphan market exclusivity in the European territory.